vigabatrin has been researched along with Abdominal Epilepsy in 115 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin (VGB) was found to be an effective anti-epileptic drug to reduce infantile spasms in about 50% of patients and it has been found most effective in infantile spasms due to tuberous sclerosis (TSC) in which up to 95% of infants had complete cessation of their spasms." | 8.81 | Vigabatrin for tuberous sclerosis complex. ( Bombardieri, R; Curatolo, P; Verdecchia, M, 2001) |
| "We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period." | 8.12 | Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? ( Chen, L; Chen, Y; Hu, Y; Liao, J; Lin, S; Liu, G; Scheffer, IE; Su, Q; Wen, F; Yao, Y; Zhao, X, 2022) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 7.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis." | 7.70 | Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000) |
| "To determine the efficacy of a new anti-epileptic medication vigabatrin in adults and children with drug-resistant epilepsy." | 7.69 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales." | 7.69 | A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. ( Gordon, GS; Schapel, GJ; Wallace, SJ, 1997) |
| "Twenty-five patients with epilepsy (mostly with partial seizures) who had responded favourably to a short-term trial of add-on vigabatrin entered maintenance treatment." | 7.68 | Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. ( Galimberti, CA; Iudice, A; Manni, R; Morini, R; Mumford, JP; Perucca, E; Tartara, A, 1992) |
| "Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients)." | 6.69 | Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. ( Cardinali, C; Zamponi, N, 1999) |
| "Vigabatrin was most effective in cryptogenic and symptomatic partial seizures (39% and 43%, respectively), and in infantile spasms (25%)." | 6.68 | Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. ( Coppola, G; Pascotto, A; Terraciano, AM, 1997) |
| "Twenty children aged 2 months to 18 years were included in a dose-response study of vigabatrin as add-on therapy to preexisting antiepileptic drugs (up to two per patient)." | 6.67 | Dose-response study of vigabatrin in children with refractory epilepsy. ( Armijo, JA; Arteaga, R; Beaumont, D; Farr, IN; Herranz, JL; Valdizan, E, 1991) |
| "To date, 27 children with partial epilepsy, two with generalized epilepsy, two with Lennox-Gastaut syndrome, and one with nonclassifiable epilepsy have been enrolled in the trial." | 6.67 | Vigabatrin in pediatric epilepsy--an open study. ( Alving, J; Beck, S; Gram, L; Uldall, P, 1991) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 6.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "The repertoire of available and developmental therapies for epilepsy is rapidly expanding, and now includes disease-modifying vigabatrin in TSC and agents with extraordinary efficacy, fenfluramine and cenobamate." | 5.41 | Recent advances in pharmacotherapy for epilepsy. ( Klein, P; Pong, AW; Xu, KJ, 2023) |
| "Vigabatrin (VGB) has been shown through several studies to be safe and effective as add-on therapy, particularly for the treatment of partial seizures in patients with severe epilepsies followed for years in hospital-based clinics." | 5.08 | Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group. ( Arzimanoglou, AA; Dumas, C; Ghirardi, L, 1997) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)." | 4.87 | Epilepsy (partial). ( Maguire, M; Marson, AG; Ramaratnam, S, 2011) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)." | 4.86 | Epilepsy (partial). ( Maguire, M; Marson, AG; Ramaratnam, S, 2010) |
| "Vigabatrin (VGB) was found to be an effective anti-epileptic drug to reduce infantile spasms in about 50% of patients and it has been found most effective in infantile spasms due to tuberous sclerosis (TSC) in which up to 95% of infants had complete cessation of their spasms." | 4.81 | Vigabatrin for tuberous sclerosis complex. ( Bombardieri, R; Curatolo, P; Verdecchia, M, 2001) |
| "More than 360 children with intractable epilepsy have been treated with vigabatrin in single-blind or open, add-on studies." | 4.78 | The role of vigabatrin in the management of infantile epileptic syndromes. ( Appleton, RE, 1993) |
| "We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period." | 4.12 | Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? ( Chen, L; Chen, Y; Hu, Y; Liao, J; Lin, S; Liu, G; Scheffer, IE; Su, Q; Wen, F; Yao, Y; Zhao, X, 2022) |
| "To review the efficacy, cognitive outcome and safety profile in children treated with vigabatrin (VGB) for infantile spasms (IS) and partial epilepsies related to tuberous sclerosis complex (TSC) and other etiologies." | 3.74 | Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. ( Camposano, SE; Halpern, E; Major, P; Thiele, EA, 2008) |
| "Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis." | 3.70 | Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000) |
| "One hundred and twenty-seven patients with uncontrolled epilepsy have been treated in an open add-on study with vigabatrin with a mean follow up of ten months." | 3.69 | Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group. ( Russ, W, 1995) |
| "A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales." | 3.69 | A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. ( Gordon, GS; Schapel, GJ; Wallace, SJ, 1997) |
| "To determine the efficacy of a new anti-epileptic medication vigabatrin in adults and children with drug-resistant epilepsy." | 3.69 | Vigabatrin use in 72 patients with drug-resistant epilepsy. ( Buchanan, N, 1994) |
| "Twenty-five patients with epilepsy (mostly with partial seizures) who had responded favourably to a short-term trial of add-on vigabatrin entered maintenance treatment." | 3.68 | Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. ( Galimberti, CA; Iudice, A; Manni, R; Morini, R; Mumford, JP; Perucca, E; Tartara, A, 1992) |
| "Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction." | 2.75 | Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy. ( Bittman, RM; Christen, EM; Sagar, SM; Sergott, RC, 2010) |
| "734 patients with refractory partial epilepsy, divided into three groups and stratified by age (8-12 years; >12 years) and exposure to vigabatrin." | 2.74 | Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. ( Ahn, H; Baulac, M; Bursztyn, J; Chiron, C; Gandolfo, E; Goldberg, I; Goñi, FJ; Mercier, F; Nordmann, JP; Perucca, E; Safran, AB; Schiefer, U; Wild, JM, 2009) |
| " Patients randomized to GBP started on 1800 mg/d and could have their dosage increased stepwise to 2400 and 3600 mg/d if seizures persisted." | 2.71 | Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. ( Johannessen, SI; Larsson, S; Lindberger, M; Luhr, O; Tomson, T, 2003) |
| "Vigabatrin is a newly licensed drug for use in patients with epilepsy." | 2.69 | Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. ( Chadwick, D, 1999) |
| "Vigabatrin (VGB) has been shown in a number of clinical trials with varying designs to be effective and well-tolerated as both add-on therapy and monotherapy in epilepsy with partial seizures with or without secondary generalization as well as in infantile spasms." | 2.69 | Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. ( Bruni, J; Guberman, A, 2000) |
| "Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients)." | 2.69 | Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. ( Cardinali, C; Zamponi, N, 1999) |
| "Vigabatrin was most effective in cryptogenic and symptomatic partial seizures (39% and 43%, respectively), and in infantile spasms (25%)." | 2.68 | Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. ( Coppola, G; Pascotto, A; Terraciano, AM, 1997) |
| "Vigabatrin therapy was ineffective in the four children with tuberous sclerosis." | 2.68 | Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures. ( Buckley, D; Hobbs, GR; Penney, S; Sheth, RD, 1996) |
| " After 1-month observation, the patients entered a 7-month treatment period that involved administration of placebo for 1 month followed by VGB at the initial dosage of 40 mg/kg/day, to be increased to 60 and 80 mg/kg/day at 2-month intervals if seizures persisted." | 2.68 | Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. ( Buti, D; Cianchetti, C; Dalla Bernardina, B; Fontana, E; Fusco, L; Galeone, D; Gnanasakthy, A; Iudice, A; Torelli, D; Vigevano, F, 1995) |
| " Vigabatrin mean dosage during phase 3 was 63." | 2.68 | Vigabatrin in refractory childhood epilepsy. The Brazilian Multicenter Study. ( Chisté, MA; da Costa, JC; Diament, A; Gherpelli, JL; Guerreiro, CA; Guerreiro, MM; Manreza, ML; Nunes, ML; Palmini, A; Pedroso, F; Reed, UC; Rotta, NT; Silva, EA; Vega-Gutiérrez, L; Vizioli, J, 1997) |
| "Vigabatrin was administered as "add on therapy" (Table 1) and monotherapy (Table 2)." | 2.67 | [Gamma-vinyl-GABA: the first trials in Italy]. ( de Romanis, F; Sopranzi, N, 1993) |
| "Vigabatrin was associated with a significant reduction in a measure of motor speed and overall score on a design learning test in the first 20 weeks of treatment." | 2.67 | Effects of vigabatrin on partial seizures and cognitive function. ( Corcoran, R; Corden, Z; Duncan, JS; Grünewald, RA; Jackson, GD; Thompson, PJ, 1994) |
| "To date, 27 children with partial epilepsy, two with generalized epilepsy, two with Lennox-Gastaut syndrome, and one with nonclassifiable epilepsy have been enrolled in the trial." | 2.67 | Vigabatrin in pediatric epilepsy--an open study. ( Alving, J; Beck, S; Gram, L; Uldall, P, 1991) |
| "Twenty children aged 2 months to 18 years were included in a dose-response study of vigabatrin as add-on therapy to preexisting antiepileptic drugs (up to two per patient)." | 2.67 | Dose-response study of vigabatrin in children with refractory epilepsy. ( Armijo, JA; Arteaga, R; Beaumont, D; Farr, IN; Herranz, JL; Valdizan, E, 1991) |
| " We evaluated: 50% or greater reduction in seizure frequency, treatment withdrawal, adverse effects, dose-response analysis, cognitive outcomes and quality of life." | 2.66 | Vigabatrin add-on therapy for drug-resistant focal epilepsy. ( Bresnahan, R; Gianatsi, M; Maguire, MJ; Marson, AG; Tudur Smith, C, 2020) |
| "Vigabatrin is an antiepileptic drug licensed for use in the treatment of refractory epilepsy." | 2.49 | Vigabatrin for refractory partial epilepsy. ( Hemming, K; Hutton, JL; Maguire, MJ; Marson, AG, 2013) |
| "Vigabatrin was rationally designed to have a specific effect on brain chemistry by inhibiting the GABA-degrading enzyme, GABA transaminase, resulting in a widespread increase in GABA concentrations in the brain." | 2.47 | Mechanism of action of vigabatrin: correcting misperceptions. ( Ben-Menachem, E, 2011) |
| "Vigabatrin was well-tolerated with generally mild AEs considered common to AEDs." | 2.47 | Vigabatrin therapy for refractory complex partial seizures: review of major European trials. ( Ben-Menachem, E; Sander, JW, 2011) |
| "Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid (GABA) transaminase." | 2.47 | Understanding and interpreting vision safety issues with vigabatrin therapy. ( Plant, GT; Sergott, RC, 2011) |
| " In clinical trials, vigabatrin was generally well-tolerated with an adverse event profile similar to that of other AEDs." | 2.47 | Non-vision adverse events with vigabatrin therapy. ( Kälviäinen, R; Walker, SD, 2011) |
| " Its efficacy in achieving improved seizure control should be apparent within 12 weeks in patients with rCPS and within 2-4 weeks after attaining appropriate dosage for patients with IS." | 2.47 | Balancing clinical benefits of vigabatrin with its associated risk of vision loss. ( Pellock, JM, 2011) |
| " Results of the US trials have demonstrated vigabatrin to be an effective and generally well-tolerated therapy for rCPS in adults, with an optimal dosage of 3 g/day for most patients, and an onset of response generally within 2 weeks." | 2.47 | Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States. ( Faught, E, 2011) |
| "Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory epilepsy and used in infantile spasms." | 2.46 | Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. ( Hemming, K; Hutton, JL; Maguire, MJ; Marson, AG; Wild, JM, 2010) |
| "Vigabatrin is an antiepileptic drug licensed for use in the treatment of refractory epilepsy." | 2.44 | Vigabatrin for refractory partial epilepsy. ( Hemming, K; Hutton, JL; Maguire, MJ; Marson, AG, 2008) |
| "Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter gamma-amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA-transaminase." | 2.40 | Vigabatrin. ( French, JA, 1999) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 2.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Vigabatrin was not shown to have any harmful effects in extensive laboratory, EEG and cognitive function tests." | 2.39 | Rationalized polytherapy for epilepsy. ( de Bittencourt, PR; Goldsmith, P, 1995) |
| " In a similarly designed United States trial, LTG was significantly superior to placebo at a 500-mg/day dosage but not at a 300-mg/day dosage." | 2.39 | Expanding antiepileptic drug options: clinical efficacy of new therapeutic agents. ( Ben-Menachem, E, 1996) |
| "Valproic acid was prescribed most frequently as first and second treatment, followed by vigabatrin." | 1.42 | Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. ( Bindels-de Heus, K; de Wit, MC; Moll, HA; Overwater, IE; Rietman, AB; Ten Hoopen, LW; Vergouwe, Y, 2015) |
| "Epileptic spasms without hypsarrhythmia have been described in some series of patients, occurring either in infancy or childhood." | 1.42 | Epileptic spasms without hypsarrhythmia in infancy and childhood: tonic spasms as a seizure type. ( Carvalho, KC; Corso, JT; Ferrari-Marinho, T; Guaranha, MS; Marchi, LR; Naves, PV; Ramirez, MD; Seraphim, EA; Yacubian, EM, 2015) |
| " In addition to demographics and vigabatrin dosing information, data included seizure type/frequency at presentation and subsequent follow-up." | 1.38 | Vigabatrin for childhood partial-onset epilepsies. ( Agricola, K; Fordyce, S; Franz, DN; Greiner, HM; Krueger, DA; Lynch, ER; Tudor, C, 2012) |
| "Nine individuals with partial epilepsy and VGB-attributed visual field loss (group 1; 18 eyes) and seven age- and gender-matched individuals with epilepsy and no previous VGB exposure (group 2; 14 eyes) were included in the study." | 1.37 | Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. ( Brodtkorb, E; Gajda, A; Hoff, JM; Midelfart, A; Moseng, L; Mørch-Johnsen, GH; Sæter, M, 2011) |
| "Epileptic seizures can be difficult to recognize in infancy and childhood because the semeiology can be misleading." | 1.35 | [Epileptic seizures in childhood: from seizure type to diagnosis]. ( Chabrol, B; Hugonencq, C; Mancini, J; Milh, M; Ticus, I; Villeneuve, N, 2008) |
| "Vigabatrin was started at a mean age of 7." | 1.35 | Visual fields at school-age in children treated with vigabatrin in infancy. ( Gaily, E; Jonsson, H; Lappi, M, 2009) |
| "Patients with intractable partial epilepsy under VGB add-on treatment received static perimetric examinations." | 1.33 | Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy. ( Huang, FC; Lai, SL; Lan, MY; Tsai, JJ; Tseng, YL, 2006) |
| "Lamotrigine is a useful add-on therapy in treating children with epilepsy." | 1.33 | The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. ( Keegan, MB; Madden, D; McDonald, DG; McMenamin, JB; Najam, Y; Whooley, M, 2005) |
| " A 6-month multicentre, open-label study, involved addition of gabapentin to pre-existing treatment at the initial dosage of 1200 mg and subsequent adjustment between 900 and 2400 mg/day according to efficacy and tolerability." | 1.30 | Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. ( Arzimanoglou, A; Baulac, M; Cavalcanti, D; Portal, JJ; Semah, F, 1998) |
| "Vigabatrin acts as an inhibitor of gamma-aminobutyric acid (GABA) transaminase." | 1.30 | Outer retinal dysfunction in patients treated with vigabatrin. ( Arndt, CF; Defoort-Dhellemmes, S; Derambure, P; Hache, JC, 1999) |
| "VGB is an effective drug for partial epilepsy." | 1.29 | Reduction of plasma alanine aminotransferase during vigabatrin treatment. ( Bachmann, C; Delisle, MC; Foletti, GB, 1995) |
| "Vigabatrin was given as first add-on drug at a dose of 2-3 g/day for an average of 6 months, in order to assess the clinical response before considering other anti-epilepsy drugs." | 1.29 | Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients. ( Iudice, A; Murri, L, 1995) |
| "A patient with focal epilepsy that was resistant to medical treatment received add-on therapy with vigabatrin." | 1.29 | [Allergic vasculitis caused by Vigabatrin]. ( Becker, EW; Berg, PA; Berkenfeld, R; Dieterle, L; Reinshagen, G, 1994) |
| "Treatment of phenytoin responders and nonresponders with other primary antiepileptic drugs showed that valproate and phenobarbital induced much smaller increases in focal seizure threshold in phenytoin nonresponders than in responders, whereas carbamazepine induced about the same threshold increase in both groups." | 1.29 | Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. ( Hönack, D; Löscher, W; Rundfeldt, C, 1993) |
| " The once daily dosing schedule was well tolerated and side effects were usually mild and always reversible." | 1.28 | Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. ( Ben-Menachem, E; Mumford, J; Persson, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.74) | 18.7374 |
| 1990's | 63 (54.78) | 18.2507 |
| 2000's | 27 (23.48) | 29.6817 |
| 2010's | 20 (17.39) | 24.3611 |
| 2020's | 3 (2.61) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, S | 1 |
| Liao, J | 1 |
| Zhao, X | 1 |
| Hu, Y | 1 |
| Chen, L | 1 |
| Chen, Y | 1 |
| Liu, G | 1 |
| Yao, Y | 1 |
| Su, Q | 1 |
| Scheffer, IE | 1 |
| Wen, F | 1 |
| Pong, AW | 1 |
| Xu, KJ | 1 |
| Klein, P | 1 |
| Bresnahan, R | 1 |
| Gianatsi, M | 1 |
| Maguire, MJ | 4 |
| Tudur Smith, C | 1 |
| Marson, AG | 6 |
| Chin, EM | 1 |
| Cohen, JS | 1 |
| Harris, J | 1 |
| Hemming, K | 3 |
| Hutton, JL | 3 |
| Marchi, LR | 1 |
| Seraphim, EA | 1 |
| Corso, JT | 1 |
| Naves, PV | 1 |
| Carvalho, KC | 1 |
| Ramirez, MD | 1 |
| Ferrari-Marinho, T | 1 |
| Guaranha, MS | 1 |
| Yacubian, EM | 1 |
| Overwater, IE | 1 |
| Bindels-de Heus, K | 1 |
| Rietman, AB | 1 |
| Ten Hoopen, LW | 1 |
| Vergouwe, Y | 1 |
| Moll, HA | 1 |
| de Wit, MC | 1 |
| Lawthom, C | 2 |
| Smith, PE | 2 |
| Wild, JM | 4 |
| Gaily, E | 1 |
| Jonsson, H | 1 |
| Lappi, M | 1 |
| Chiron, C | 5 |
| Ahn, H | 1 |
| Baulac, M | 2 |
| Bursztyn, J | 1 |
| Gandolfo, E | 2 |
| Goldberg, I | 1 |
| Goñi, FJ | 1 |
| Mercier, F | 1 |
| Nordmann, JP | 1 |
| Safran, AB | 1 |
| Schiefer, U | 2 |
| Perucca, E | 3 |
| Sergott, RC | 3 |
| Bittman, RM | 1 |
| Christen, EM | 1 |
| Sagar, SM | 1 |
| Moseng, L | 1 |
| Sæter, M | 1 |
| Mørch-Johnsen, GH | 1 |
| Hoff, JM | 1 |
| Gajda, A | 1 |
| Brodtkorb, E | 1 |
| Midelfart, A | 1 |
| Besch, D | 1 |
| Eter, N | 1 |
| Burth, R | 1 |
| Elger, CE | 2 |
| Spitznas, M | 1 |
| Dietz, K | 1 |
| Maguire, M | 2 |
| Ramaratnam, S | 2 |
| Shields, WD | 1 |
| Pellock, JM | 2 |
| Ben-Menachem, E | 5 |
| Faught, E | 1 |
| Sander, JW | 2 |
| Plant, GT | 1 |
| Westall, CA | 1 |
| Walker, SD | 1 |
| Kälviäinen, R | 4 |
| Greiner, HM | 1 |
| Lynch, ER | 1 |
| Fordyce, S | 1 |
| Agricola, K | 1 |
| Tudor, C | 1 |
| Franz, DN | 1 |
| Krueger, DA | 1 |
| Weber, P | 1 |
| Dill, P | 1 |
| Datta, AN | 1 |
| Arndt, CF | 2 |
| Salle, M | 1 |
| Derambure, PH | 1 |
| Defoort-Dhellemmes, S | 2 |
| Hache, JC | 2 |
| van Rijckevorsel, K | 1 |
| Boon, PA | 1 |
| Deda, G | 1 |
| Caksen, H | 1 |
| Lindberger, M | 2 |
| Luhr, O | 1 |
| Johannessen, SI | 2 |
| Larsson, S | 2 |
| Tomson, T | 2 |
| Papadeas, E | 1 |
| Polychronopoulos, P | 1 |
| Papathanasopoulos, P | 1 |
| Frimas, C | 1 |
| Pharmakakis, N | 1 |
| Paschalis, C | 1 |
| McDonagh, J | 1 |
| Stephen, LJ | 1 |
| Dolan, FM | 1 |
| Parks, S | 1 |
| Dutton, GN | 1 |
| Kelly, K | 1 |
| Keating, D | 1 |
| Sills, GJ | 1 |
| Brodie, MJ | 3 |
| McDonald, DG | 1 |
| Najam, Y | 1 |
| Keegan, MB | 1 |
| Whooley, M | 1 |
| Madden, D | 1 |
| McMenamin, JB | 1 |
| Pojda-Wilczek, D | 1 |
| Emich-Widera, E | 1 |
| Herba, E | 1 |
| Pojda, SM | 1 |
| Marszał, E | 1 |
| Tseng, YL | 1 |
| Lan, MY | 1 |
| Lai, SL | 1 |
| Huang, FC | 1 |
| Tsai, JJ | 1 |
| Macleod, S | 1 |
| Appleton, RE | 2 |
| Milh, M | 1 |
| Ticus, I | 1 |
| Villeneuve, N | 1 |
| Hugonencq, C | 1 |
| Mancini, J | 1 |
| Chabrol, B | 1 |
| Camposano, SE | 1 |
| Major, P | 1 |
| Halpern, E | 1 |
| Thiele, EA | 1 |
| Hawker, MJ | 1 |
| Astbury, NJ | 1 |
| Goldsmith, P | 1 |
| de Bittencourt, PR | 1 |
| Murri, L | 1 |
| Iudice, A | 3 |
| Ylinen, A | 2 |
| Riekkinen, PJ | 2 |
| Dalla Bernardina, B | 1 |
| Fontana, E | 1 |
| Vigevano, F | 1 |
| Fusco, L | 1 |
| Torelli, D | 1 |
| Galeone, D | 2 |
| Buti, D | 1 |
| Cianchetti, C | 1 |
| Gnanasakthy, A | 1 |
| Russ, W | 1 |
| Foletti, GB | 1 |
| Delisle, MC | 1 |
| Bachmann, C | 1 |
| Marciani, MG | 2 |
| Maschio, M | 2 |
| Spanedda, F | 2 |
| Iani, C | 1 |
| Gigli, GL | 1 |
| Bernardi, G | 2 |
| Devinsky, O | 1 |
| Vazquez, B | 1 |
| Luciano, D | 1 |
| Vogt, H | 1 |
| Krämer, G | 1 |
| Buchanan, N | 3 |
| Grünewald, RA | 1 |
| Thompson, PJ | 1 |
| Corcoran, R | 1 |
| Corden, Z | 1 |
| Jackson, GD | 1 |
| Duncan, JS | 1 |
| Sälke-Kellermann, A | 1 |
| Baier, H | 1 |
| Rambeck, B | 1 |
| Boenigk, HE | 1 |
| Wolf, P | 1 |
| Cocito, L | 1 |
| Maffini, M | 1 |
| Loeb, C | 1 |
| Dieterle, L | 1 |
| Becker, EW | 1 |
| Berg, PA | 1 |
| Berkenfeld, R | 1 |
| Reinshagen, G | 1 |
| Löscher, W | 1 |
| Rundfeldt, C | 1 |
| Hönack, D | 1 |
| Ring, HA | 1 |
| Crellin, R | 1 |
| Kirker, S | 1 |
| Reynolds, EH | 2 |
| de Romanis, F | 1 |
| Sopranzi, N | 1 |
| Kearney, B | 1 |
| Walker, MC | 1 |
| Cockerell, OC | 2 |
| Vallat, C | 1 |
| Rivier, F | 1 |
| Bellet, H | 1 |
| Magnan de Bornier, B | 1 |
| Mion, H | 1 |
| Echenne, B | 1 |
| Hughes, D | 1 |
| Sheth, RD | 1 |
| Buckley, D | 1 |
| Penney, S | 1 |
| Hobbs, GR | 1 |
| Schapel, G | 1 |
| Chadwick, D | 2 |
| Malmgren, K | 2 |
| Hedström, A | 1 |
| Granqvist, R | 1 |
| Malmgren, H | 1 |
| Dulac, O | 4 |
| Gram, L | 3 |
| Stanzione, P | 1 |
| Bassetti, MA | 1 |
| Mattia, D | 1 |
| Veggiotti, P | 3 |
| De Agostini, G | 1 |
| Baldi, PL | 1 |
| Muzio, C | 1 |
| Lanzi, G | 3 |
| Nabbout, RC | 1 |
| Mumford, J | 3 |
| Dumas, C | 3 |
| Arzimanoglou, AA | 1 |
| Ghirardi, L | 1 |
| Coppola, G | 1 |
| Terraciano, AM | 1 |
| Pascotto, A | 1 |
| Gherpelli, JL | 1 |
| Guerreiro, MM | 1 |
| da Costa, JC | 1 |
| Rotta, NT | 1 |
| Manreza, ML | 1 |
| Reed, UC | 1 |
| Diament, A | 1 |
| Silva, EA | 1 |
| Guerreiro, CA | 1 |
| Nunes, ML | 1 |
| Palmini, A | 1 |
| Vega-Gutiérrez, L | 1 |
| Vizioli, J | 1 |
| Pedroso, F | 1 |
| Chisté, MA | 1 |
| Schapel, GJ | 1 |
| Wallace, SJ | 1 |
| Gordon, GS | 1 |
| Cavalcanti, D | 1 |
| Semah, F | 1 |
| Arzimanoglou, A | 1 |
| Portal, JJ | 1 |
| Bauer, J | 1 |
| Scherrmann, J | 1 |
| Widman, G | 1 |
| Ruether, K | 1 |
| Pung, T | 1 |
| Kellner, U | 1 |
| Schmitz, B | 1 |
| Hartmann, C | 1 |
| Seeliger, M | 1 |
| Jambaqué, I | 2 |
| Kaminska, A | 1 |
| Plouin, P | 1 |
| Matagne, A | 1 |
| Klitgaard, H | 1 |
| Bélanger, S | 1 |
| Coulombe, G | 1 |
| Carmant, L | 1 |
| Leppik, IE | 1 |
| Mumford, JP | 3 |
| Derambure, P | 1 |
| Gobbi, G | 1 |
| Pini, A | 1 |
| Bertani, G | 1 |
| Menegati, E | 1 |
| Tiberti, A | 1 |
| Valseriati, D | 2 |
| Besana, D | 1 |
| Rasmini, P | 1 |
| Guerrini, R | 1 |
| Belmonte, A | 1 |
| Resi, C | 1 |
| Capovilla, G | 1 |
| Milani, S | 1 |
| Zamponi, N | 1 |
| Cardinali, C | 1 |
| Versino, M | 1 |
| Roubergue, A | 1 |
| Pelosse, B | 1 |
| Doummar, D | 1 |
| Beauvais, P | 1 |
| Montchilova, M | 1 |
| Gonthier, B | 1 |
| Billette de Villemeur, T | 1 |
| Nousiainen, I | 2 |
| Mäntyjärvi, M | 2 |
| Nikoskelainen, E | 1 |
| Partanen, J | 1 |
| Partanen, K | 1 |
| Riekkinen, P | 1 |
| White, HS | 1 |
| French, JA | 1 |
| Elferink, AJ | 1 |
| Toivonen, M | 1 |
| van Bronswijk, H | 1 |
| Panayiotopoulos, CP | 1 |
| Hirsch, E | 1 |
| Guberman, A | 1 |
| Bruni, J | 1 |
| Alenius, M | 1 |
| Frisén, L | 1 |
| Giordano, L | 1 |
| Vignoli, A | 1 |
| Morescalchi, F | 1 |
| Kmieć, T | 1 |
| Jóźwiak, S | 1 |
| Kuczyński, D | 1 |
| Karkowska, B | 1 |
| Bachański, M | 1 |
| Curatolo, P | 1 |
| Verdecchia, M | 1 |
| Bombardieri, R | 1 |
| Sheean, G | 1 |
| Schramm, T | 1 |
| Anderson, DS | 1 |
| Eadie, MJ | 1 |
| Tartara, A | 2 |
| Manni, R | 2 |
| Galimberti, CA | 2 |
| Morini, R | 1 |
| Michelucci, R | 1 |
| Tassinari, CA | 1 |
| Sivenius, J | 1 |
| Murros, K | 1 |
| Uldall, P | 1 |
| Alving, J | 1 |
| Beck, S | 1 |
| Herranz, JL | 1 |
| Arteaga, R | 1 |
| Farr, IN | 1 |
| Valdizan, E | 1 |
| Beaumont, D | 1 |
| Armijo, JA | 1 |
| Persson, L | 1 |
| Cosi, V | 1 |
| Callieco, R | 1 |
| Balottin, U | 1 |
| Klosterskov, P | 1 |
| Dam, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial[NCT04302116] | 250 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | |||
| Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial[NCT03689114] | Phase 4 | 374 participants (Anticipated) | Interventional | 2020-01-07 | Not yet recruiting | ||
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| The Effect of Gabapentin on Prefrontal GABA Concentration and Emotional Processing in Healthy Humans[NCT00094510] | 30 participants (Actual) | Observational | 2004-10-14 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for vigabatrin and Abdominal Epilepsy
| Article | Year |
|---|---|
Recent advances in pharmacotherapy for epilepsy.
Topics: Adult; Anticonvulsants; Child; Epilepsies, Myoclonic; Epilepsies, Partial; Epilepsy; Fenfluramine; H | 2023 |
Vigabatrin add-on therapy for drug-resistant focal epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dizziness; Drug Resistant Epilepsy; Drug Therapy, Combina | 2020 |
Vigabatrin for refractory partial epilepsy.
Topics: Anticonvulsants; Drug Resistance; Epilepsies, Partial; Humans; Randomized Controlled Trials as Topic | 2013 |
Vigabatrin for refractory partial epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Randomized Controlled Trials as Topic; Vigabatrin | 2008 |
Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
Topics: Adult; Anticonvulsants; Child; Drug Resistance; Epilepsies, Partial; Female; Humans; Male; Prevalenc | 2010 |
Epilepsy (partial).
Topics: Anticonvulsants; Clinical Trials as Topic; Cost-Benefit Analysis; Epilepsies, Partial; Epilepsy; Hum | 2010 |
Epilepsy (partial).
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Humans; Phenytoin; Vigabatrin | 2011 |
Mechanism of action of vigabatrin: correcting misperceptions.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anticonvulsants; Drug Administration Schedule; Epilepsies, | 2011 |
Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States.
Topics: Adult; Anticonvulsants; Ataxia; Clinical Trials as Topic; Dizziness; Drug Administration Schedule; E | 2011 |
Vigabatrin therapy for refractory complex partial seizures: review of major European trials.
Topics: Adult; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Epilepsies, Partial; GABA Age | 2011 |
Understanding and interpreting vision safety issues with vigabatrin therapy.
Topics: 4-Aminobutyrate Transaminase; Adult; Animals; Anticonvulsants; Causality; Comorbidity; Confounding F | 2011 |
Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
Topics: Adult; Anticonvulsants; Electroretinography; Epilepsies, Partial; GABA Agents; Humans; Infant; Spasm | 2011 |
Non-vision adverse events with vigabatrin therapy.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Animals; Anticonvulsants; Brain Diseases; Cognition | 2011 |
Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
Topics: Adult; Animals; Anticonvulsants; Child; Epilepsies, Partial; Humans; Infant; Magnetic Resonance Imag | 2011 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
Rationalized polytherapy for epilepsy.
Topics: Anticonvulsants; Brain; Drug Therapy, Combination; Electroencephalography; Epilepsies, Partial; gamm | 1995 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
[Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, | 1995 |
The role of vigabatrin in the management of infantile epileptic syndromes.
Topics: Aminocaproates; Anticonvulsants; Child, Preschool; Epilepsies, Partial; Epilepsy; Humans; Infant; Sp | 1993 |
Expanding antiepileptic drug options: clinical efficacy of new therapeutic agents.
Topics: Anticonvulsants; Controlled Clinical Trials as Topic; Double-Blind Method; Drug Administration Sched | 1996 |
A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cost Control; Cyclohexanecarboxylic Acids; Epilepsies, Partial; G | 1996 |
Aggravation of focal epileptic seizures by antiepileptic drugs.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 1998 |
Role of new and established antiepileptic drugs.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsies, Partial; Epilepsy | 1998 |
Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Epilepsies, Partial; Felbamate; Fru | 1999 |
Vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Anticonvulsants; Brain Chemistry; Clinical Trials as Topic; Cognition; | 1999 |
Vigabatrin for tuberous sclerosis complex.
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; Humans; Infant; Tuberous Sclerosis; Vi | 2001 |
Gamma-vinyl GABA (vigabatrin): clinical experience in adult and adolescent patients with intractable epilepsy.
Topics: Adolescent; Adult; Age Factors; Aminocaproates; Anticonvulsants; Chronic Disease; Epilepsies, Partia | 1992 |
31 trials available for vigabatrin and Abdominal Epilepsy
| Article | Year |
|---|---|
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Drug Monitoring; Epilepsies, Partial; | 2009 |
Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Topics: Anticonvulsants; Child; Epilepsies, Partial; Female; Follow-Up Studies; Humans; International Cooper | 2010 |
Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study.
Topics: Acetates; Amines; Anticonvulsants; Chromatography, High Pressure Liquid; Cyclohexanecarboxylic Acids | 2003 |
Peripheral retinal dysfunction in patients taking vigabatrin.
Topics: Adult; Aged; Cohort Studies; Color Perception; Dose-Response Relationship, Drug; Electroretinography | 2003 |
Long-term efficacy and cognitive effects of vigabatrin.
Topics: Anticonvulsants; Carbamazepine; Cognition; Dose-Response Relationship, Drug; Drug Administration Sch | 1995 |
Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study.
Topics: Anticonvulsants; Child; Child, Preschool; Data Interpretation, Statistical; Epilepsies, Partial; Fem | 1995 |
Effects of vigabatrin on partial seizures and cognitive function.
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Double-Blind Method; Epilepsies, Partial; Female; gam | 1994 |
Vigabatrin in chronic epilepsy: a 7-year follow-up study of responder patients.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Drug Therapy, Combination; Electroencephalograph | 1993 |
[Gamma-vinyl-GABA: the first trials in Italy].
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Chronic Disease; Drug Therapy, Combination; Epil | 1993 |
Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures.
Topics: Adolescent; Adult; Child; Child, Preschool; Enzyme Inhibitors; Epilepsies, Partial; Epilepsy, Genera | 1996 |
Vigabatrin withdrawal randomized study in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Epilepsies, Partial; Epil | 1996 |
Vigabatrin in partial seizures in children.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Prescho | 1997 |
Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Epilepsies, Partial; Female; gamma-Aminobutyric Aci | 1997 |
Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combinat | 1997 |
Vigabatrin in refractory childhood epilepsy. The Brazilian Multicenter Study.
Topics: Adolescent; Anticonvulsants; Brazil; Child; Child, Preschool; Epilepsies, Partial; Epilepsy, General | 1997 |
Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Double-Blind Method; Drug Resistance | 1999 |
Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Electroencephalography; Epileps | 1999 |
Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children.
Topics: Administration, Oral; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; | 1999 |
Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Double-Blind Method; Epilepsies, Par | 1999 |
Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.
Topics: Adolescent; Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Epilepsies, Partial; Female | 1999 |
Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers.
Topics: Adult; Aged; Analysis of Variance; Anticonvulsants; Carbamazepine; Contrast Sensitivity; Epilepsies, | 2000 |
Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.
Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Epilepsies, Partial; Follow-Up Studies; Hum | 2000 |
Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Doub | 2000 |
[Gabitril as an additive drug in therapy of intractable epileptic seizures in children].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Drug Therapy, Combi | 2000 |
Vigabatrin--plasma enantiomer concentrations and clinical effects.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Epilepsies, Partial; Epilepsy, Complex Partial; | 1992 |
Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Pa | 1992 |
Vigabatrin.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Child; Double-Blind Method; Drugs, Investigation | 1991 |
Vigabatrin in pediatric epilepsy--an open study.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
Dose-response study of vigabatrin in children with refractory epilepsy.
Topics: Adolescent; Aminocaproates; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dr | 1991 |
Effect of vigabatrin (gamma-vinyl-GABA) on visual, brainstem auditory and somatosensory evoked potentials in epileptic patients.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Brain Stem; Child; Clinical Trials as Topic; Dou | 1988 |
gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; E | 1985 |
57 other studies available for vigabatrin and Abdominal Epilepsy
| Article | Year |
|---|---|
Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures?
Topics: Anticonvulsants; Child; Epilepsies, Partial; Humans; Infant; Retrospective Studies; Seizures; Treatm | 2022 |
Vigabatrin as a Targeted Treatment of GABA
Topics: Animals; Anticonvulsants; Chromosomes, Human, Pair 9; Drug Substitution; Electroencephalography; Epi | 2019 |
Epileptic spasms without hypsarrhythmia in infancy and childhood: tonic spasms as a seizure type.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Epilepsies, Partial; Humans; Infant; Male; Oxcarba | 2015 |
Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diet, Ketogenic; Epilepsies, Partial; Epilepsy | 2015 |
In utero exposure to vigabatrin: no indication of visual field loss.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epilepsies, Partial; Fe | 2009 |
Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Axons; Biomarkers; Carbamazepine; Cross-Sectional Studies; | 2009 |
Visual fields at school-age in children treated with vigabatrin in infancy.
Topics: Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Sche | 2009 |
Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Topics: Adult; Anticonvulsants; Epilepsies, Partial; Female; Follow-Up Studies; Humans; Male; Middle Aged; N | 2011 |
Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Cross-Sectional Studies; Epilepsies, Partial; Femal | 2011 |
Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations.
Topics: Adult; Anticonvulsants; Epilepsies, Partial; History, 20th Century; History, 21st Century; Humans; I | 2011 |
Vigabatrin for childhood partial-onset epilepsies.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsies, Partial; Female; Follow-Up | 2012 |
Vigabatrin-induced forced normalization and psychosis--prolongated termination of behavioral symptoms but persistent antiepileptic effect after withdrawal.
Topics: Adolescent; Anticonvulsants; Behavioral Symptoms; Brain Waves; Electroencephalography; Epilepsies, P | 2012 |
The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Electrooculography; Electroretinog | 2002 |
The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Cyclohexanecarboxylic Ac | 2002 |
Atypical benign partial epilepsy of childhood (pseudo-Lennox syndrome): report of two brothers.
Topics: Anticonvulsants; Child, Preschool; Electroencephalography; Epilepsies, Partial; Epilepsy, Rolandic; | 2002 |
Sensorineural hearing loss: a reversible effect of vigabatrin.
Topics: Adolescent; Anticonvulsants; Audiometry; Epilepsies, Partial; Hearing Loss, Sensorineural; Humans; M | 2003 |
The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood.
Topics: Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2005 |
[The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epilepsies, Partial; Fe | 2005 |
Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy.
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Epilepsies, Partial; Female; Humans; Male; Middle A | 2006 |
[Epileptic seizures in childhood: from seizure type to diagnosis].
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Diagnosis, Differential; Electroencephalography; Ep | 2008 |
Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Topics: Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroretinography; Epilepsies, Part | 2008 |
The ocular side effects of vigabatrin (Sabril): information and guidance for screening.
Topics: Anticonvulsants; Epilepsies, Partial; Female; Humans; Male; Vigabatrin; Vision Disorders; Vision Scr | 2008 |
Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedul | 1995 |
Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administrati | 1995 |
Reduction of plasma alanine aminotransferase during vigabatrin treatment.
Topics: Adolescent; Adult; Alanine; Alanine Transaminase; Anticonvulsants; Blood Glucose; Epilepsies, Partia | 1995 |
Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: an electroencephalographic study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain; Carbamazepine; Delta Rhythm; Electroencephalography | 1995 |
Vigabatrin use in 72 patients with drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilep | 1994 |
Acute encephalopathy with vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aminocaproates; Anticonvulsants; Carbamazepine; Com | 1993 |
[Allergic vasculitis caused by Vigabatrin].
Topics: Adult; Aminocaproates; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedu | 1994 |
Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy.
Topics: Amino Acids; Aminocaproates; Amygdala; Animals; Anticonvulsants; Carbamazepine; Disease Models, Anim | 1993 |
Vigabatrin and depression.
Topics: Adult; Aminocaproates; Anticonvulsants; Depressive Disorder; Epilepsies, Partial; Female; Humans; Ma | 1993 |
Vigabatrin in drug-resistant epilepsy.
Topics: 4-Aminobutyrate Transaminase; Adult; Aminocaproates; Anticonvulsants; Child; Epilepsies, Partial; Ep | 1993 |
Vigabatrin in the Sturge Weber syndrome.
Topics: Adult; Aminocaproates; Anticonvulsants; Child, Preschool; Epilepsies, Partial; Female; Humans; Male; | 1993 |
Vigabatrin and carbamazepine monotherapy for newly diagnosed epilepsy.
Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Electroencephalography; Epilepsies | 1996 |
Treatment with vigabatrin may mimic alpha-aminoadipic aciduria.
Topics: 2-Aminoadipic Acid; 4-Aminobutyrate Transaminase; Amino Acid Metabolism, Inborn Errors; Anticonvulsa | 1996 |
A survey comparing lamotrigine and vigabatrin in everyday clinical practice.
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Epile | 1996 |
Cost analysis of epilepsy surgery and of vigabatrin treatment in patients with refractory partial epilepsy.
Topics: Adult; Anticonvulsants; Cost-Benefit Analysis; Demography; Epilepsies, Partial; Female; gamma-Aminob | 1996 |
EEG changes induced by vigabatrin monotherapy in focal epilepsy.
Topics: 4-Aminobutyrate Transaminase; Adult; Analysis of Variance; Anticonvulsants; Case-Control Studies; El | 1997 |
Vigabatrin and psychosis: is there a true correlation?
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; gamma-Aminobutyric Acid; Humans; Psych | 1997 |
A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, P | 1997 |
Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1998 |
Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
Topics: Adolescent; Anticonvulsants; Electroretinography; Epilepsies, Partial; gamma-Aminobutyric Acid; Huma | 1998 |
Transient motor aphasia and recurrent partial seizures in a child: language recovery upon seizure control.
Topics: Anticonvulsants; Aphasia, Broca; Brain; Carbamazepine; Child; Child Language; Epilepsies, Partial; g | 1998 |
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Cornea; Disease Models, Animal; Dizocilpine Malea | 1998 |
Role of vigabatrin and lamotrigine in treatment of childhood epileptic syndromes.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 1998 |
Outer retinal dysfunction in patients treated with vigabatrin.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Electrooculography; Electroretinography; Epilepsies | 1999 |
Reversibility of vigabratin-induced visual-field defect.
Topics: Anticonvulsants; Child; Epilepsies, Partial; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Hum | 1999 |
[Severe constriction of the visual field associated with vigabatrin discovered by thorough examination of a 17-year old girl].
Topics: Adolescent; Anticonvulsants; Epilepsies, Partial; Female; gamma-Aminobutyric Acid; Hemiplegia; Human | 1999 |
Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Humans; Risk Assessment; Vigabatr | 1999 |
Importance of specifying the type of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child; Contraindications; Diagnosis, Differential; Epilepsies, Parti | 1999 |
Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.
Topics: Anticonvulsants; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Drug Therapy, Com | 2000 |
Outer retinal dysfunction in patients treated with vigabatrin.
Topics: Anticonvulsants; Epilepsies, Partial; Humans; Retinal Diseases; Vigabatrin | 2000 |
Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
Topics: Adolescent; Anticonvulsants; Epilepsies, Partial; Female; Humans; Vigabatrin; Vision Disorders; Visu | 2000 |
Management strategies for refractory localization-related seizures.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug T | 2001 |
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Brain Stem; Cerebral Cortex; Electroencephalogra | 1992 |
Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Drug Resistance; Epilepsies, Partial; Follow-Up | 1991 |
Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy.
Topics: Adolescent; Adult; Aminocaproates; Epilepsies, Partial; Female; Humans; Male; Middle Aged; Time Fact | 1990 |